A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
Christopher A BarkerSandra P D'AngeloGloria WasilewskiAlexa M StecklerMing LianZhigang ZhangPaul B ChapmanAlexander N ShoushtariCharlotte E AriyanPublished in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2024)
Low overall response rate, slow accrual, and the COVID-19 pandemic led to closure of this trial. Responses in non-injected and non-irradiated metastases were infrequent.